Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Fineline Cube May 21, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Deals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Fineline Cube Jan 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML

Fineline Cube Jan 21, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...

Company Deals

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Fineline Cube Jan 21, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...

Company Drug

Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA

Fineline Cube Jan 21, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...

Company Deals

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

Fineline Cube Jan 21, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...

Policy / Regulatory

NHSA Outlines 2025 Work Plan and 2024 Medical Insurance Status

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) last week held a press conference, addressing questions regarding...

Company Drug

FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma

Fineline Cube Jan 20, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...

Company Deals Medical Device

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Fineline Cube Jan 20, 2025

US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...

Company Drug

MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis

Fineline Cube Jan 20, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...

Policy / Regulatory

Tianjin Healthcare Official Gao Xue Under Investigation

Fineline Cube Jan 20, 2025

Gao Xue, director of the National High-value Medical Consumables Joint Procurement Office, member of the...

Medical Device Policy / Regulatory

US BIS Imposes Export Controls on Biotech Lab Instruments

Fineline Cube Jan 20, 2025

The Department of Commerce’s Bureau of Industry and Security (BIS) of the United States last...

Company

Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...

Company Drug

FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC

Fineline Cube Jan 20, 2025

US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...

Company Drug

Luye Pharma Launches Erzofri in US Market

Fineline Cube Jan 20, 2025

China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study

Fineline Cube Jan 20, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...

Company Deals

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain

Fineline Cube Jan 20, 2025

Xinzeyuan Medical Technology Co., Ltd, a minimally invasive surgical supply chain platform enterprise based in...

Company Drug

Zai Lab’s KarXT NDA Accepted by NMPA for Schizophrenia Treatment

Fineline Cube Jan 20, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that a New Drug...

Company Drug

Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study

Fineline Cube Jan 20, 2025

Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

Wanbangde’s Huperzine A Receives FDA Clearance for HIE Study

Fineline Cube Jan 20, 2025

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced receiving clearance from the...

Company Drug

FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment

Fineline Cube Jan 20, 2025

Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...

Posts pagination

1 … 227 228 229 … 669

Recent updates

  • Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.